Integrating nanotechnology with naturally occurring phytochemicalsin neuropathy induced by diabetes

• Published in: Journal of molecular liquids 2022-03, Vol.350, Article 118189
• Main Authors: Shoaib, Ambreen, Azmi, Lubna, Pal, Sampita, Alqahtani, Saad S., Rahamathulla, Mohamed, Hani, Umme, Alshehri, Sultan, Ghoneim, Mohammed M., Shakeel, Faiyaz
• Format: Article
• Language: English
• Subjects: Biocompatibility; Diabetic neuropathy; Nanoformulation; Phytomedicine
• ISSN: 0167-7322; 1873-3166
• DOI: 10.1016/j.molliq.2021.118189

•Diabetic neuropathic syndrome is the most prevalent neuropathic pain.•Nanoformulations of phytochemicals and plant extracts.•Beneficial role of nanoformulations of phytopharmaceuticals in diabetic neuropathy.•In vitro and in vivo studies on phytonanopharmaceuticals. Diabetic neuropathy is associated with a high rate of morbidity and death. The diabetic neuropathic syndrome is the most prevalent neuropathic condition. It is a distal symmetric, mostly sensory type that is the primary cause of foot ulceration and infection. Neuropathic pain is often devastating, resulting in significant discomfort and loss of function, as well as a loss of sleep of 3–5 h. This review highlights the promising natural compounds, utilized for the treatment of diabetic neuropathic pain in conjunction with the implementation of advanced nano-engineering to surpass their clinical limitations. The processes that enhance body weight, insulin sensitivity, and cell function with a plant-based nanoformulations are described. The systematic literature search on nanotechnology-based phytopharmaceuticals for the treatment of diabetic neuropathy was performed using different serach engines. Several treatment techniques have been tried, but the occurrence and danger of the disease continue to rise. Several plant-derived small molecules have been hypothesized to be useful in the treatment of diabetes and its accompanying vascular problems by working on a variety of therapeutic targets. Furthermore, the biocompatibility of these phytochemicals is raising interest in using them as therapeutic mediators. However, these phytochemicals' pharmacokinetic and biopharmaceutical properties limit their clinical use as therapeutic agents. By overcoming the pharmacokinetic and biopharmaceutical barriers associated with plant-derived antidiabetic drugs, nanotechnology is the best strategy for improving compliance and clinical effectiveness. Patients with diabetic neuropathy will benefit from practical factors such as education, adequate diet, and medication adjustments.